Cannabis Improved Parkinson's Tremor and Movement Within 30 Minutes
Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study
Bottom Line
Smoked cannabis produced rapid, significant improvement across all major Parkinson's motor symptoms in a small observational study — but the lack of a control group means the placebo effect cannot be ruled out.
Why It Matters
This was one of the first studies to quantify cannabis's motor benefit in Parkinson's using a standardized clinical rating scale, providing objective data for what had previously been only anecdotal reports.
The Backstory
Parkinson's disease takes your body from you slowly. The tremor that starts in one hand. The stiffness that makes getting out of a chair feel like lifting concrete. The bradykinesia — the slowing of movement — that turns everyday tasks into exhausting negotiations with muscles that won't cooperate.
The standard treatments work, for a while. Levodopa replaces the dopamine the brain can no longer produce. But it takes weeks to titrate, the effects fluctuate ("on-off" phenomenon), and after years of use, the side effects — dyskinesias, hallucinations, wearing-off episodes — can become as debilitating as the disease itself.
So when 22 patients at a Tel Aviv clinic smoked cannabis and showed measurable motor improvement within thirty minutes, the speed of the response alone was enough to make neurologists pay attention.
The Study
Itay Lotan and colleagues at the Rabin Medical Center (Beilinson Hospital), affiliated with Tel Aviv University's Sackler Faculty of Medicine, conducted a straightforward observational study. Twenty-two patients with Parkinson's disease were evaluated before and 30 minutes after smoking cannabis using the gold-standard assessment tool: the Unified Parkinson Disease Rating Scale (UPDRS).
The study design was simple — perhaps too simple, as its critics would note. No control group. No blinding. No placebo. Patients smoked their regular medical cannabis (these were existing medical cannabis users at the clinic) and were assessed before and after. What the study lacked in methodological rigor, it made up for in the clarity of its results.
The Results
The improvement was dramatic and rapid.
30%
reduction in mean UPDRS motor score — from 33.1 at baseline to 23.2 after cannabis — a 10-point improvement achieved within 30 minutes of smoking.
For context, a 3-5 point improvement on the UPDRS motor score is generally considered clinically meaningful. A 10-point improvement represents a substantial change in motor function — comparable to the best response to optimized levodopa therapy.
Lotan et al. (2014), Clin Neuropharmacol
Every major motor domain improved:
No serious adverse effects were reported. The improvement was consistent across the cohort — not a few dramatic responders pulling up the average, but a widespread pattern of benefit.
Why This Makes Biological Sense
The endocannabinoid system is deeply wired into the basal ganglia — the brain circuit that Parkinson's disease destroys. The basal ganglia contain some of the highest densities of CB1 receptors in the entire brain, and endocannabinoids serve as critical modulators of the dopaminergic, glutamatergic, and GABAergic signaling that controls movement.
The paradox is that CB1 activation in the basal ganglia theoretically inhibits dopamine release — which should make Parkinson's symptoms worse, not better. The resolution may lie in the complexity of the circuit: by modulating GABAergic and glutamatergic neurons in the striatum, cannabis may improve the net output of the motor circuit even while reducing dopamine release at specific synapses. The basal ganglia isn't a simple on/off switch — it's a multi-layered feedback loop, and cannabinoid modulation appears to improve the loop's overall function even through mechanisms that seem counterintuitive in isolation.
The Limitations — And They're Significant
This study is compelling, but it has limitations that demand caution.
The placebo problem is especially acute in Parkinson's research. PD patients show unusually strong placebo responses — sometimes as large as the drug effect — because expectation alone can transiently increase dopamine release in the depleted striatum. Patients who already used and believed in medical cannabis would be particularly susceptible to this effect.
The selection bias compounds the issue: these were patients who had already chosen to use medical cannabis and who presumably felt it helped them. Patients who tried cannabis and found it unhelpful or unpleasant would not be in this clinic. The study captured the best-case population, not a representative sample of all PD patients.
What Happened Next
Despite its limitations, the Lotan study was one of the most-discussed cannabis-for-PD papers because it provided something the field lacked: quantified motor improvement using a standardized assessment tool. Previous evidence consisted mainly of patient surveys and case reports.
Several randomized controlled trials have since been launched or completed:
- A Czech Republic RCT of smoked cannabis in PD found mixed results — some motor benefit but inconsistent across patients
- CBD-specific trials have explored neuroprotection and non-motor symptoms (sleep, psychosis, quality of life)
- A 2019 survey of 40+ PD patients in Israel found 75% reported motor improvement with cannabis, consistent with Lotan's findings but still lacking placebo control
The challenge facing cannabis-for-PD research is the same challenge that plagues the broader field: blinding. You cannot truly blind a cannabis study when the treatment produces obvious psychoactive effects. Until someone solves the blinding problem — perhaps with CBD-only formulations or balanced THC:CBD preparations where psychoactivity is minimal — the placebo question will hang over every positive finding.
What This Means for Patients
For people living with Parkinson's disease, this study offers something valuable even with its limitations: a documented, quantified record of rapid motor improvement from cannabis in a clinical setting. The improvement was not subtle — a 30% reduction in motor severity within 30 minutes is clinically meaningful by any standard.
The practical appeal for PD patients is obvious: existing medications take weeks to optimize, fluctuate unpredictably ("on" and "off" periods are a hallmark of advanced PD), and accumulate side effects over years. Cannabis showed near-immediate effect, improved multiple symptom domains simultaneously (motor, sleep, pain), and produced no serious adverse events in this cohort.
But the responsible message is this: a 22-person open-label study is not enough to change clinical guidelines. It's enough to justify the randomized trials that are now underway. PD patients considering cannabis should discuss it with their neurologist, start with low doses, and recognize that the strong evidence base is still being built.
Key Takeaways
Cite this study
Lotan I, Treves TA, Roditi Y, Djaldetti R. (2014). Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clinical Neuropharmacology. https://doi.org/10.1097/WNF.0000000000000016